Shopping Cart
- Remove All
Your shopping cart is currently empty
CL-A3-7
😃Good
Catalog No. T201641Cas No. 2763661-39-6
CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.
CL-A3-7
😃Good
Catalog No. T201641Cas No. 2763661-39-6
CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CL-A3-7"
Brigatinib
Cited
AP-26113
T36211197953-54-0
Brigatinib (AP-26113) is a highly potent and selective inhibitor of ALK.
- $30
Size
QTY
CitedRibavirin Cited
Tribavirin, RTCA, NSC-163039, ICN-1229
T068436791-04-5
Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.
- $39
Size
QTY
CitedRoflumilast Cited
BYK 20869, BY 217, B9302-107, APTA 2217
T1024162401-32-3
Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.
- $50
Size
QTY
CitedTyrphostin AG 538
AG 538
T67707133550-18-2In house
Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (ICâ‚…0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.
- $100
Size
QTY
Ceritinib Cited
LDK378
T17911032900-25-6
Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.
- $45
Size
QTY
CitedGSK1904529A Cited
GSK 4529
T60031089283-49-7In house
GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
- $34
Size
QTY
CitedALK-IN-1
Brigatinib-analog, AP26113-analog, AP26113
T30591197958-12-5
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
- $40
Size
QTY
Indirubin Derivative E804
T11654854171-35-0In house
Indirubin Derivative E804 is a potent insulin-like growth factor type 1 receptor (IGF1R) inhibitor with potential antitumor activity.
- $42
Size
QTY
PD173074 Cited
T2642219580-11-7
PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
- $36
Size
QTY
CitedAmentoflavone Cited
Didemethyl-ginkgetin, Amenthoflavone, 3',8''-Biapigenin
T34171617-53-4
Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.
AntibacterialAntifungalApoptosisCOXCytochromes P450Opioid ReceptorPhospholipaseReactive Oxygen SpeciesRSV
- $30
Size
QTY
CitedLinsitinib
Cited
OSI-906
T6017867160-71-2
OSI-906 (Linsitinib (OSI-906)) is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.
- $33
Size
QTY
CitedHNMPA
T21761132541-52-7In house
HNMPA is a membrane impermeable inhibitor of insulin receptor tyrosine kinase. HNMPA inhibits tyrosine and serine autophosphorylation by the human insulin receptor. HNMPA exhibits no effect on cyclic AMP-dependent protein kinase or protein kinase C activities.
- $43
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV. |
| Molecular Weight | 584.25 |
| Formula | C24H22Br2F2N2O3 |
| Cas No. | 2763661-39-6 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CL-A3-7 | purchase CL-A3-7 | CL-A3-7 cost | order CL-A3-7 | CL-A3-7 chemical structure | CL-A3-7 formula | CL-A3-7 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.